Form 4: Mirum Director Boosts Stake Post-Merger

Mirum Pharmaceuticals director Patrick J. Heron increased his indirect beneficial ownership through a merger-related share receipt and a significant share purchase.

Summary

• Patrick J. Heron, a Director of Mirum Pharmaceuticals, Inc., reported changes in his beneficial ownership.
• On January 23, 2026, Frazier Life Sciences X, L.P., an entity in which Mr. Heron is a managing member, received 159,277 shares of Common Stock in connection with the merger of Bluejay Therapeutics, Inc. into Mirum Pharmaceuticals.
• The closing price of Mirum's Common Stock on the effective date of the merger was $94.29 per share.
• Also on January 23, 2026, Frazier Life Sciences X, L.P. purchased an additional 131,425 shares of Common Stock at a price of $68.48 per share.
• Following these transactions, Mr. Heron's indirect beneficial ownership includes 459,010 shares held by Frazier Life Sciences X, L.P., 3,566,912 shares held by Frazier Life Sciences IX, L.P., and 5,703 shares held directly.
• Mr. Heron disclaims beneficial ownership of the indirectly held securities except to the extent of his pecuniary interest.

Sentiment

Score: 8

Explanation: The significant increase in a director's indirect beneficial ownership, including a substantial purchase, indicates strong insider confidence in the company's value and future prospects, especially following a merger.

Positives

• A director, Patrick J. Heron, increased his indirect beneficial ownership in Mirum Pharmaceuticals through both a merger-related share receipt and an open market purchase.
• The purchase of 131,425 shares at $68.48 indicates confidence in the company's valuation by an insider.
• The acquisition of Bluejay Therapeutics, Inc. suggests strategic growth and expansion for Mirum Pharmaceuticals.

Negatives

• The purchase price of $68.48 per share is lower than the closing price of $94.29 on the merger effective date, which could imply a perceived discount or a different valuation context for the purchase.

Future Outlook

The filing does not provide specific forward-looking statements or guidance, but the acquisition of Bluejay Therapeutics, Inc. suggests a strategic move for future growth.

Management Comments

• The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Industry Context

The acquisition of Bluejay Therapeutics, Inc. by Mirum Pharmaceuticals indicates consolidation or strategic expansion within the biotechnology or pharmaceutical sector, a common trend for companies seeking to broaden their pipeline or market reach.

Related Party Transactions

• Patrick J. Heron, a managing member of the general partners of Frazier Life Sciences X, L.P. and Frazier Life Sciences IX, L.P., indirectly holds shares through these entities. These transactions represent an indirect related party dealing due to his affiliation with the investment funds.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive signal, potentially boosting investor confidence.
• The merger with Bluejay Therapeutics, Inc. could impact employees of both entities through integration processes.
• The strategic acquisition may enhance Mirum's product pipeline, potentially benefiting future customers.

Key Dates

Recommendation

The significant increase in a director's beneficial ownership, particularly through a substantial purchase, signals strong insider confidence in the company's valuation and future performance, especially in the context of a recent strategic merger. This insider buying activity often precedes positive company developments.

Keywords

Mirum Pharmaceuticals, MIRM, Insider Trading, Form 4, Director Share Purchase, Beneficial Ownership, Merger, Bluejay Therapeutics, Frazier Life Sciences